Savara, Inc. (SVRA): Price and Financial Metrics
GET POWR RATINGS... FREE!
SVRA Stock Price Chart Interactive Chart >
SVRA Price/Volume Stats
|Current price||$2.39||52-week high||$2.82|
|Prev. close||$2.52||52-week low||$1.02|
|Day high||$2.54||Avg. volume||334,112|
|50-day MA||$1.86||Dividend yield||N/A|
|200-day MA||$1.54||Market Cap||272.57M|
Savara, Inc. (SVRA) Company Bio
Savara Inc., a clinical-stage specialty pharmaceutical company, focuses on the development and commercialization of novel therapies for the treatment of serious or life-threatening rare respiratory diseases. The company is based in Austin, Texas.
Most Popular Stories View All
SVRA Latest News Stream
|Loading, please wait...|
SVRA Latest Social Stream
View Full SVRA Social Stream
Latest SVRA News From Around the Web
Below are the latest news stories about SAVARA INC that investors may wish to consider to help them evaluate SVRA as an investment opportunity.
The clinical-stage biopharmaceutical company focuses on therapies to treat rare respiratory diseases.
AUSTIN, Texas, January 20, 2023--Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced the grant of inducement awards to two new employees.
Private equity firms are Savara Inc.'s (NASDAQ:SVRA) biggest owners and were rewarded after market cap rose by US$25m last week
If you want to know who really controls Savara Inc. ( NASDAQ:SVRA ), then you'll have to look at the makeup of its...
In a report released today, Andrew Fein from H.C. Wainwright reiterated a Buy rating on Savara (SVRA - Research Report), with a price target of $3.00. The company's shares closed last Friday at $1.17.Fein covers the Healthcare sector, focusing on stocks such as Unity Biotechnology, Wave Life Sciences, and ACADIA Pharmaceuticals. According to TipRanks, Fein has an average return of -10.6% and a 35.48% success rate on recommended stocks. Currently, the analyst consensus on Savara is a Moderate Buy with an average price target of $3.00.
AUSTIN, Texas, November 10, 2022--Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, reported financial results for the third quarter ending September 30, 2022 and provided a business update.
SVRA Price Returns